At first, it felt like a whisper campaign. Rumors really.
Then celebrities were talking about it. Then influencers. Then suddenly it felt like everyone was on it.
You know a medication has reached cultural status when The Simpsons devote an entire episode to it (Season 36, Episode 13).
In my own practice, the shift was obvious. Discovery calls started sounding like this:
“Should I do a nutrition plan… OR just go on Ozempic?”
“Hey what are your thoughts on Wegovy?”
Then I started having friends and clients sheepishly admit they were starting the medication. As it became more mainstream, the tone shifted. It was no longer whispered, it was celebrated.
One client in particular stands out. She had been facing serious liver concerns, and her physician made it clear that if things did not change, she’d be in dire straights. That conversation shook her. She committed wholeheartedly — nutrition, movement, supplementation, sleep. She did everything we outlined. Over time, her labs normalized. The same physician who had delivered the warning was genuinely impressed by what she achieved through lifestyle intervention.
And then one day she excitedly said to me, “I don’t really need to diet or supplement anymore. I’m on semaglutide now and I can eat whatever I want!”
I was stunned.
GLP-1 agonists hit like a wonder drug, a miracle cure. Like many of us in the wellness space, at first, I reeled. Then I leaned in. Because the simple fact is: GLP-1 receptor agonists are not going anywhere.
And here’s the thing: the data are compelling. In large, randomized trials, semaglutide and tirzepatide have produced average weight reductions in the 15–22% range, along with improvements in glycemic control and, in high-risk populations, cardiovascular outcomes [1,2,3]. These drugs do deliver results.
It becomes our job to understand this class of drugs so we can help clients understand the risks, reap the benefits, and avoid the pitfalls. So the question for us is not whether we “like” them.
The question is: how do we support clients who are using them? How do we demystify the hype and frame it as a powerful tool?
As functional practitioners, we are skeptical of short cuts. We revere root causes. But GLP-1 agonists aren’t cheat codes. They’re catalysts with the potential to break barriers and deliver meaningful opportunities.
They deserve respect. And like any hormone-modulating therapy, they demand more foundational support, not less.
The aim of this post is to reassure practitioners navigating this new world that GLP-1 agonists offer significant benefits but they absolutely do not replace root cause care. In fact, your clients need you more than ever. Having an educated guide supporting someone through their journey can be the difference between being a success story or a cautionary tale.
Supporting clients on GLP-1? This practitioner guide walks you through the 5 key questions to ask before building any protocol so you can assess digestion, hydration, metabolic health, and more. Because GLP-1s don’t replace root-cause care… they amplify it.
Respect the Physiology
GLP-1 (glucagon-like peptide-1) is an incretin hormone released from the gut in response to food intake. It stimulates insulin secretion when glucose is elevated, suppresses glucagon, delays gastric emptying, and signals satiety through central appetite pathways. It has many other effects in the body as well, beyond the scope of this post. Native GLP-1 has a very short half-life — roughly one to two minutes — because it is rapidly degraded by DPP-4 enzymes.[5,6]
GLP-1 receptor agonists are structurally modified to resist that breakdown. They are hormone mimetics, meaning they imitate and prolong the signaling effects of the body’s own GLP-1.[5,6]
In concept, this is somewhat similar to how SSRIs prolong serotonin signaling — not by creating more serotonin, but by allowing it to remain active at receptor sites longer. Likewise, GLP-1 agonists don’t create a new pathway; they prolong and intensify an existing satiety signal.
When we extend that signal, we extend its physiologic effects: food stays in the stomach longer, appetite decreases, postprandial glucose excursions flatten.[5,6]
As practitioners, we know hormones don’t work in isolation. They operate within networks of feedback, balance, and counterbalance; the Goldilocks principle absolutely applies. More is not better; just right is better.
Many of the side effects attributed to GLP-1 therapy are less about the medication itself and more about how quickly the dose is escalated relative to an individual’s tolerance.[7]
Standardized titration schedules provide a framework, but we know physiology is not standardized. In most areas of endocrine care, hormone therapies are adjusted thoughtfully and in response to individual feedback. Escalating insulin or thyroid therapy without feedback would be considered irresponsible. The same principle applies here: what feels appropriate for one client may be excessive for another.[7]
While prescribing decisions belong solely to the doctor managing the medication, it is well within our scope to help clients recognize patterns and communicate effectively. If a client reports overwhelming nausea, inability to consume enough food, severe constipation, or profound fatigue, those may be indicators that dose or titration speed warrants reevaluation. Encouraging an open dialogue with the prescriber — for example, asking whether a slower titration or lower maintenance dose might be appropriate — can dramatically improve tolerability.[7]
At the same time, not every symptom signals dysfunction.
When a client experiences earlier satiety, mild transient nausea, reduced interest in heavy foods, or slightly slower bowel movements, those are direct extensions of GLP-1 physiology.[8] The medication slows gastric emptying and amplifies satiety signaling. Some degree of these experiences is expected.
The clinical task is not to eliminate all discomfort. It is to differentiate between physiologic effect and physiologic overwhelm.
Mild, tolerable changes often indicate the drug is doing what it was designed to do. Persistent, debilitating symptoms suggest the signal may be too strong for that individual’s current terrain. Think for example of someone who needs support to prioritize nutrition because they now tend to undereat vs someone who lost their appetite so completely they can barely manage eating at all.
Our role is to help clients navigate that distinction — supporting digestion, nourishment, hydration, and muscle preservation while collaborating appropriately with the prescribing clinician.
Full Doesn’t Mean Fueled
This is where functional support becomes indispensable. The mechanisms of GLP-1 therapy are beneficial, but they can also amplify preexisting imbalances when nourishment is not intentional.
Many of the most common complaints associated with GLP-1 use — muscle loss, hair thinning, fatigue, brittle nails, low energy, increased susceptibility to constipation, even mood shifts — make physiologic sense when viewed through a different lens. In many cases, they are not mysterious adverse reactions. They are signs of undernourishment.
One of the most significant risks is loss of lean mass.
In calorie-restricted weight loss scenarios, approximately 20–30% of total weight lost is typically lean tissue.[9] This phenomenon is not unique to GLP-1 therapy; it is a feature of under-eating. However, when appetite is significantly suppressed, the risk becomes easier to overlook.
Clients often feel successful because the scale is moving. They may feel relief that intrusive food thoughts have quieted. But when protein intake drops, when meals become small and inconsistent because “I’m just not hungry,” or when clients unintentionally skip meals altogether, predictable downstream effects follow: declining muscle mass, fatigue, thinning hair, brittle nails, decreased exercise tolerance, etc.
Fatigue then reduces movement. Reduced movement accelerates further muscle loss. The cycle compounds quietly.
This is why body composition matters more than scale weight. Preserving lean mass is not cosmetic—it is metabolic infrastructure. Skeletal muscle improves insulin sensitivity, supports mitochondrial function, influences resting energy expenditure, and provides protection against weight regain.[9,10] If lean mass is not protected during weight loss, a client may reach a lower number on the scale yet emerge metabolically more impaired than at the start of therapy.
For clients using GLP-1 medications, education around nutrient sufficiency is absolutely critical.
Appetite suppression narrows the margin for error. In simple terms: if bites are limited, then every bite has to count. When intake volume decreases, nutrient density must increase. Dense protein sources can feel heavy when early satiety arrives quickly, and when appetite is very low, clients often gravitate toward foods that feel easier to consume — typically refined carbohydrates or highly processed options. Over time, this crowds out muscle-preserving protein and micronutrient-rich foods.[10]Remember that client who told me “I can eat whatever I want!” Well, whatever she wanted was not protein rich or nutrient dense.
Practitioners play a pivotal role in helping clients prioritize macronutrient adequacy within a smaller intake window. This may include setting individualized protein targets, encouraging protein-forward meal structure, reinforcing resistance training, and monitoring for early signs of lean mass decline. [9,10] Bioimpedance scales are an affordable tool to help clients track. Though not 100% accurate, they offer practical trend data that can help identify early lean mass loss and guide timely intervention.
When nourishment is intentional, many of the complaints commonly attributed to GLP-1 therapy — including hair loss and fatigue — become far less common.
Remember: full does not necessarily mean fueled. Many clients who have long relied on appetite cues to guide intake now find themselves in unfamiliar territory, where hunger is muted and internal signals are quieter. Thoughtful education helps them learn how to nourish their bodies even when appetite is no longer leading the way.
Digestion: The Overlooked Variable
Because GLP-1 agonists slow gastric emptying, clients with pre-existing digestive compromise often struggle the most.
If someone already has low hydrochloric acid production, suboptimal enzyme output, sluggish biliary flow, SIBO, or chronic constipation, slowing motility further can magnify symptoms. Food lingers. Bloating increases. Reflux worsens. Bowel movements become less frequent.[11]
Often, these symptoms reflect the mechanism—until they exceed a client’s tolerance.
The work becomes supporting digestive capacity so that slower emptying does not translate into stagnation. Optimizing protein digestion, assessing biliary sufficiency, encouraging movement to support peristalsis — these are not optional add-ons. They are central to tolerability. [11]
Hydration matters as well. Appetite suppression often blunts thirst cues, which can compound constipation and fatigue. It’s a simple example of how foundational support changes tolerability.
Rapid Weight Loss and Gallbladder Risk
One area where conventional and functional perspectives align is gallstone formation during rapid weight loss. Accelerated fat mobilization increases cholesterol saturation in bile and reduces gallbladder motility, both of which raise gallstone risk approximately 1.5-2 fold.[12]
This risk is not specific to GLP-1 medications; it is seen with very-low-calorie diets and bariatric surgery as well. [12] The concern arises when rapid weight loss is driven by aggressive caloric restriction or overly rapid dose escalation that eliminates appetite entirely. Supporting adequate intake and pacing weight loss helps mitigate this risk. Assessing biliary function is key.
The Neurologic Dimension
One of the most profound — and often welcome — effects of GLP-1 therapy is the reduction in “food noise.” Clients describe a quieting of obsessive thoughts around food. This aligns with the presence of GLP-1 receptors in brain regions involved in reward and appetite regulation.[13]
In some individuals, however, the dampening of reward signaling appears to extend beyond food. Anecdotally and in emerging reports, higher doses may be associated with reduced libido, decreased motivation, or a sense of emotional blunting. While research is still evolving, this likely reflects broader modulation of dopaminergic pathways rather than a psychiatric disorder.
I recall an extreme case of a client reporting she was thrilled to be losing weight, but when I questioned her deeper she reported that she just laid in bed all day. She skipped her favorite yoga classes. Food had no appeal. She didn’t want to do anything. It was as if she’d lost her spark entirely. She didn’t realize that was an effect of the medication. After her doctor lowered her dose, she began engaging again. I found it so interesting that she initially still reported success on the medication because of her weight loss. You just can’t overstate the power weight has on our self-perception!
The important clinical point is this: if a client reports a loss of “zest” for life, we do not dismiss it. We encourage conversation with the prescriber. Often, dose adjustment restores balance while preserving metabolic benefit. [14,15]
The “Coming Off” Conversation
Perhaps the most pressing question practitioners are now encountering is: what happens when the medication stops?
Extension data from semaglutide trials demonstrate that without significant lifestyle support, people gain about two thirds of their weight back within one year of going off the medication.[16,17] Biology pushes back. Appetite increases. Energy expenditure shifts. Without muscle preservation and behavioral reinforcement, weight returns.
This does not mean people should never discontinue therapy. It does mean that discontinuation should be intentional. Before tapering, we should ask: do they have healthy lean mass? Has the client built sustainable eating patterns? Is strength training consistent? Are sleep and stress reasonably regulated? Has inflammation been addressed? Is digestion and gut health optimized?
For some individuals, particularly those with longstanding type 2 diabetes or significant cardiometabolic risk, long-term pharmacotherapy may be appropriate. For others, gradual tapering with close monitoring can succeed. It’s important not to frame this as success or failure, but simply a response to feedback.
Our role is not to promise that lifestyle alone will override biology. It is to help build enough metabolic resilience that if the medication is reduced, the terrain is stronger than it was at the start.
The Bigger Conversation
GLP-1 agonists reduce visceral fat. They improve glycemic control. They lower cardiovascular risk in high-risk populations. They quiet compulsive eating signals.[1-4, 18]
For many clients, that means hope, sometimes for the first time in years.
But these medications do NOT replace protein intake. They do not build muscle. They do not correct circadian disruption, heal trauma, remove ultra-processed food from the environment, restore mitochondrial function, optimize digestion, or regulate stress. In other words, they do not correct root cause imbalances that may have led to insufficient GLP-1 production in the first place.
They amplify whatever terrain they are placed upon, strong foundations or unstable ones.
When foundational physiology is supported, outcomes improve and side effects diminish. When foundations are neglected, fragility becomes visible quickly and clients are left in yet another cycle of loss and regain and overall health decline — even if they do so in a smaller pant size.
Clinical Takeaway: You are the missing piece
This is where thoughtful clinical strategy matters most. As functional practitioners, we are uniquely positioned in this moment. A root-cause framework, informed by comprehensive lab data and individualized protocols, allows us to support the physiology that GLP-1 medications influence. When that deeper terrain is addressed — digestion, muscle preservation, metabolic flexibility, inflammation, circadian rhythm — the outcomes clients hope for become far more likely and sustainable.
At the Institute of Restorative Health, our commitment is to equip practitioners with the clinical depth and confidence to navigate complex metabolic cases, whether a client arrives seeking foundational healing alone or alongside pharmacologic support. The ability to work with labs effecively, build strategic protocols, and think physiologically allows you to meet this evolving landscape with clarity rather than hesitation. Yes, GLP-1 agonists have changed the landscape in many ways, but they did not replace you in the wellness space. They raised the stakes and made skilled, root-cause practitioners indispensable.
Supporting clients on GLP-1? This practitioner guide walks you through the 5 key questions to ask before building any protocol so you can assess digestion, hydration, metabolic health, and more. Because GLP-1s don’t replace root-cause care… they amplify it.
FAQ
These FAQs expand on key clinical considerations to help practitioners confidently support clients using GLP-1 receptor agonists.
What are GLP-1 receptor agonists and how do they work in the body?
GLP-1 receptor agonists are medications that mimic and prolong the effects of the body’s natural GLP-1 hormone. They enhance insulin secretion, suppress glucagon, delay gastric emptying, and increase satiety. This results in reduced appetite and improved blood sugar regulation.
What clinical benefits are associated with GLP-1 medications like semaglutide and tirzepatide?
GLP-1 medications are associated with significant weight loss and improved metabolic markers. Clinical trials show average weight reductions of 15–22%, along with improvements in glycemic control and cardiovascular outcomes in high-risk populations.
Do GLP-1 receptor agonists replace the need for lifestyle and root-cause care?
No, GLP-1 medications do not replace foundational lifestyle or root-cause interventions. They act as catalysts, but do not address underlying issues like digestion, inflammation, or metabolic dysfunction. Ongoing clinical support remains essential.
How should practitioners think about GLP-1 therapy within a functional medicine framework?
GLP-1 therapy should be viewed as a tool that amplifies existing physiology. It requires stronger foundational support, not less, including nutrition, digestion, and metabolic health. Outcomes depend heavily on the underlying terrain.
How can practitioners differentiate between expected effects and problematic side effects?
Expected effects include early satiety, mild nausea, and slower bowel movements. Problematic symptoms include persistent nausea, inability to eat, severe constipation, or fatigue, which may indicate excessive dosing or poor tolerance.
Why do some clients experience fatigue, hair loss, or muscle loss on GLP-1 medications?
These symptoms are often signs of undernourishment rather than direct drug effects. Appetite suppression can reduce protein and nutrient intake, leading to downstream effects like muscle loss, fatigue, and hair thinning.
Why is lean mass preservation critical during GLP-1–induced weight loss?
Preserving lean mass is essential for metabolic health and long-term weight stability. Skeletal muscle supports insulin sensitivity, mitochondrial function, and energy expenditure. Loss of lean mass increases the risk of metabolic decline and weight regain.
What nutritional strategies are most important for clients on GLP-1 therapy?
Nutrient density and protein intake become critical when appetite is suppressed.
- Individualized protein targets
- Protein-forward meal structure
- Consistent meal timing despite low hunger
How do GLP-1 medications impact digestion and gastrointestinal function?
GLP-1 medications slow gastric emptying, which can affect digestion. This may lead to increased bloating, reflux, or constipation, especially in clients with pre-existing digestive issues.
Which clients are most likely to experience digestive challenges on GLP-1 therapy?
Clients with pre-existing digestive dysfunction are at higher risk. This includes those with low stomach acid, enzyme insufficiency, sluggish bile flow, SIBO, or chronic constipation.
What role does hydration play in GLP-1 tolerability?
Hydration is critical for managing common side effects like constipation and fatigue. Appetite suppression can also blunt thirst cues, making intentional hydration necessary.
Is there an increased risk of gallstones with GLP-1 medications?
Yes, rapid weight loss can increase gallstone risk by 1.5–2 times. This occurs due to increased cholesterol in bile and reduced gallbladder motility, particularly with aggressive caloric restriction.
How do GLP-1 medications affect the brain and behavior around food?
GLP-1 medications reduce “food noise” by acting on brain regions involved in appetite and reward. In some cases, this effect may extend to reduced motivation, libido, or emotional engagement.
What should practitioners monitor if clients report emotional blunting or low motivation?
Clients reporting reduced “zest” or motivation should be referred back to their prescriber. Dose adjustments often restore balance while maintaining metabolic benefits.
What happens when clients stop GLP-1 medications?
Most clients regain a significant portion of weight after discontinuation without lifestyle support. Studies show approximately two-thirds of weight can return within one year if foundational habits are not established.
How can practitioners support successful discontinuation of GLP-1 therapy?
Successful discontinuation requires building metabolic resilience before tapering.
- Adequate lean mass
- Consistent nutrition and strength training
- Stable sleep, stress, and digestion
References
[1] Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
[2] Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413. doi:10.1001/jama.2021.1831
[3] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
[4] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563
[5] Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. doi:10.1016/j.cmet.2018.03.001
[6] Nauck MA, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes—state-of-the-art. Mol Metab. 2021;46:101102. doi:10.1016/j.molmet.2020.101102
[7] Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224
[8] Adverse Effects of GLP-1 Receptor Agonists. In: Endotext Internet. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279102/
[9] Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719-1730. doi:10.1056/NEJMoa2028198
[10] Pasiakos SM, Cao JJ, Margolis LM, et al. Effects of high-protein diets on fat-free mass and muscle protein synthesis following weight loss: a randomized controlled trial. FASEB J. 2013;27(9):3837-3847. doi:10.1096/fj.13-230227
[11] Camilleri M. Gastrointestinal hormones and regulation of gastric emptying. Curr Opin Endocrinol Diabetes Obes. 2019;26(1):1-10. doi:10.1097/MED.0000000000000448
[12] Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14(2):110-121. doi:10.1038/nrgastro.2016.181
[13] Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. doi:10.1016/j.molmet.2019.09.010
[14] Anorgasmia following initiation of GLP-1 agonist: a case report. J Sex Med. 2025;22(7):1234-1240. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12260840/
[15] Cone JJ, Roitman MF. Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety. Science. 2025;389(6699):eadt0773. doi:10.1126/science.adt0773
[16] Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725
[17] West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304. Published 2026 Jan 7. doi:10.1136/bmj-2025-085304
[18] Tchang BG, Aras M, Kumar RB, Aronne LJ. Pharmacologic Treatment of Overweight and Obesity in Adults. In: Feingold KR, Adler RA, Ahmed SF, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; August 20, 2024.
ABOUT THE AUTHOR:
Kristin Whitaker
NTM, MRHP, BCHN
Kristin’s journey into holistic nutrition was sparked by her determination to help her own family overcome a host of gut and autoimmune challenges. As a mom of four teenagers, Kristin understands firsthand the toll that imbalances can take on both individuals and the family as a whole. Her relentless pursuit of answers led her to graduate from the Nutrition Therapy Institute in 2020 and dive deeply into advanced studies with the Institute of Restorative Health, where she completed all four levels of certification and now serves as an instructor.
